SCHEMBL6542520

SCHEMBL6542520

CC(C)(C)NC(=O)c1cc(CNc2ncccc2C(=O)Nc2cc3ccccc3cn2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 5/20 0.48
KDR P35968 15/20 0.44
CIT O14578 1/20 0.41
MAP3K7 O43318 1/20 0.41
RIPK2 O43353 1/20 0.41
STK10 O94804 1/20 0.41
MAP4K4 O95819 1/20 0.41
ABL1 P00519 1/20 0.41
EGFR P00533 1/20 0.41
RAF1 P04049 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
CSF1R P07333 1/20 0.41
YES1 P07947 1/20 0.41
LYN P07948 1/20 0.41
RET P07949 1/20 0.41
HCK P08631 1/20 0.41
PDGFRB P09619 1/20 0.41
FGR P09769 1/20 0.41
KIT P10721 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542828 0.88 KDR (0.49) KDRCITMAP3K7RIPK2STK10
SCHEMBL6543388 0.87 KIT (0.48) KDRCITMAP3K7RIPK2STK10
SCHEMBL446890 0.83 KDR (0.63) KDRCITMAP3K7RIPK2STK10
SCHEMBL1490923 0.83 KIT (0.51) KDRCITMAP3K7RIPK2STK10
SCHEMBL6542861 0.81 KIT (0.49) KDRCITMAP3K7RIPK2STK10
SCHEMBL6542481 0.80 KDR (0.45) ANO1KDR
SCHEMBL6543102 0.78 KDR (0.45) KDRCITMAP3K7RIPK2STK10
SCHEMBL3106983 0.77 KDR (0.46) KDR
SCHEMBL4036764 0.76 FLT1 (0.51) KDRKITBRAFFLT1
SCHEMBL13772049 0.76 KIT (0.50) KDRKITBRAFFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 FLT4, KDR, FLT1 ANO1 3295/4885KDR 2/4885CIT 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.